Clinical study of NM441 in respiratory tract infection

K. Shimokata, S. Ichiyama, S. Sakai, F. Nomura, K. Senda, M. Yamamoto, S. Yamori, T. Shibagaki, M. Sato, T. Murate, K. Imaizumi, E. Takagi, Y. Inagaki, N. Yurikusa

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


NM441, a new prodrug type of quinolone antibiotic, was administered to 23 patients with respiratory tract infection, and its clinical efficacy, bacteriological efficacy, side effects and abnormal changes in laboratory findings were investigated in 22 cases. Twenty-two patients were studied and consisted of 3 cases of acute bronchitis, 11 of bacterial pneumonia, 4 of chronic bronchitis, 2 of brinchiectasis, 1 of secondary infection of pulmonary emphysema and 1 of mycoplasma pneumonia. Clinical efficacy was evaluated as excellent in 6 cases, good in 12, fair in 1 and poor in 3, and the efficacy rate was 81.8%. In bacteriological efficacy, a total of 5 strains, 3 of Haemophilus influenzae and 2 of Streptococcus pneumoniae, were isolated from 5 patients, and all of them were eradicated. Side effects were observed in 3 cases; 1 of discomfort in the mouth and diminished appetite, 1 of loose stool and 1 of dizziness. Abnormal changes in laboratory findings were observed in 3 cases; 2 of increase of eosinophil and 1 of mild elevation of GOT. We propose that NM441 is a useful drug for respiratory tract infections.

Original languageEnglish
Pages (from-to)617-621
Number of pages5
JournalJapanese Journal of Chemotherapy
Issue numberSUPPL. 1
Publication statusPublished - 1996
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Clinical study of NM441 in respiratory tract infection'. Together they form a unique fingerprint.

Cite this